Do analysts prefer EXOZ or PASG?

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 187.79%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is EXOZ or PASG more profitable?

Passage Bio's return on equity of -218.59% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Passage Bio N/A -218.59% -72.93%

Does the media prefer EXOZ or PASG?

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 0.93 beat Passage Bio's score of 0.63 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PASG or INMB?

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 187.79%. Given Passage Bio's higher possible upside, equities analysts clearly believe Passage Bio is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is PASG or INMB more profitable?

INmune Bio's return on equity of -82.87% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -218.59% -72.93% INmune Bio N/A -82.87% -62.23%

Does the media favor PASG or INMB?

In the previous week, INmune Bio had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Passage Bio. INmune Bio's average media sentiment score of 1.13 beat Passage Bio's score of 0.63 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IMMP or PASG?

Prima BioMed has higher revenue and earnings than Passage Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.04 -$39.78M N/A N/A Passage Bio N/A N/A -$45.52M -$11.32 N/A

Is IMMP or PASG more profitable?

Prima BioMed's return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Passage Bio N/A -218.59% -72.93%

Does the media prefer IMMP or PASG?

In the previous week, Prima BioMed had 3 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for Prima BioMed and 2 mentions for Passage Bio. Prima BioMed's average media sentiment score of 0.72 beat Passage Bio's score of 0.63 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ELTX or PASG?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A Passage Bio N/A N/A -$45.52M -$11.32 N/A

Is ELTX or PASG more profitable?

Passage Bio's return on equity of -218.59% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Passage Bio N/A -218.59% -72.93%

Does the media prefer ELTX or PASG?

In the previous week, Elicio Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Elicio Therapeutics and 2 mentions for Passage Bio. Elicio Therapeutics' average media sentiment score of 0.72 beat Passage Bio's score of 0.63 indicating that Elicio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, INKT or PASG?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A Passage Bio N/A N/A -$45.52M -$11.32 N/A

Is INKT or PASG more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Passage Bio N/A -218.59% -72.93%

Passage Bio (PASG) Competitors

$4.60 +0.08 (+1.86%)

As of 09:30 AM Eastern

Compare

PASG vs. EXOZ, INMB, IMMP, ELTX, and INKT

Should you buy Passage Bio stock or one of its competitors? Passage Bio's main competitors and comparable companies include eXoZymes (EXOZ), INmune Bio (INMB), Prima BioMed (IMMP), Elicio Therapeutics (ELTX), and MiNK Therapeutics (INKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Passage Bio compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 187.79%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

eXoZymes has higher revenue and earnings than Passage Bio. eXoZymes is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 0.93 beat Passage Bio's score of 0.63 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a beta of 2.93, indicating that its stock price is 193% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

53.5% of Passage Bio shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Passage Bio's return on equity of -218.59% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Passage Bio	N/A	-218.59%	-72.93%

Summary

Passage Bio beats eXoZymes on 7 of the 13 factors compared between the two stocks.

How does Passage Bio compare to INmune Bio?

Passage Bio (NASDAQ:PASG) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

In the previous week, INmune Bio had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Passage Bio. INmune Bio's average media sentiment score of 1.13 beat Passage Bio's score of 0.63 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

INmune Bio's return on equity of -82.87% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-218.59%	-72.93%
INmune Bio	N/A	-82.87%	-62.23%

Passage Bio has higher earnings, but lower revenue than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A
INmune Bio	$50K	1,248.20	-$45.93M	-$0.67	N/A

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 187.79%. Given Passage Bio's higher possible upside, equities analysts clearly believe Passage Bio is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Passage Bio has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

INmune Bio beats Passage Bio on 9 of the 15 factors compared between the two stocks.

How does Passage Bio compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Prima BioMed has higher revenue and earnings than Passage Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

In the previous week, Prima BioMed had 3 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for Prima BioMed and 2 mentions for Passage Bio. Prima BioMed's average media sentiment score of 0.72 beat Passage Bio's score of 0.63 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed presently has a consensus price target of $5.50, suggesting a potential upside of 1,406.85%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 187.79%. Given Prima BioMed's higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Prima BioMed's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Passage Bio	N/A	-218.59%	-72.93%

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Prima BioMed has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Summary

Prima BioMed beats Passage Bio on 8 of the 12 factors compared between the two stocks.

How does Passage Bio compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Elicio Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Elicio Therapeutics and 2 mentions for Passage Bio. Elicio Therapeutics' average media sentiment score of 0.72 beat Passage Bio's score of 0.63 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 599.12%. Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 187.79%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Elicio Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Elicio Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Passage Bio's return on equity of -218.59% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Passage Bio	N/A	-218.59%	-72.93%

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

Summary

Elicio Therapeutics beats Passage Bio on 8 of the 13 factors compared between the two stocks.

How does Passage Bio compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Passage Bio had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 2 mentions for Passage Bio and 1 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.87 beat Passage Bio's score of 0.63 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Very Positive
Passage Bio	Positive

MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 203.16%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 187.79%. Given MiNK Therapeutics' higher possible upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Passage Bio	N/A	-218.59%	-72.93%

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

Summary

Passage Bio beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.77M	$3.94B	$7.18B	$12.88B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.41	11.68	273.17	25.44
Price / Sales	N/A	1,401.93	637.42	103.51
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.78	16.92	11.08	6.36
Net Income	-$45.52M	-$22.74M	$3.48B	$349.79M
7 Day Performance	2.08%	-0.13%	0.21%	-0.48%
1 Month Performance	3.00%	11.45%	7.75%	4.17%
1 Year Performance	-35.43%	55.66%	24.68%	15.11%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	3.6075 of 5 stars	$4.60 +1.9%	$13.25 +187.8%	-36.6%	$14.77M	N/A	N/A	130	Gap Down
EXOZ eXoZymes	0.7649 of 5 stars	$6.38 +5.7%	N/A	-26.1%	$58.71M	N/A	N/A	29	Gap Down
INMB INmune Bio	0.7967 of 5 stars	$2.12 -0.7%	N/A	+14.8%	$58.70M	N/A	N/A	10
IMMP Prima BioMed	2.844 of 5 stars	$0.40 +2.7%	$5.50 +1,285.4%	-76.3%	$58.51M	$6.69M	N/A	2,021	News Coverage Upcoming Earnings Short Interest Decrease
ELTX Elicio Therapeutics	2.5689 of 5 stars	$3.06 +1.5%	$19.75 +544.6%	-73.0%	$58.49M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. EXOZ, INMB, IMMP, ELTX, and INKT

How does Passage Bio compare to eXoZymes?

Summary

How does Passage Bio compare to INmune Bio?

Summary

How does Passage Bio compare to Prima BioMed?

Summary

How does Passage Bio compare to Elicio Therapeutics?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. EXOZ, INMB, IMMP, ELTX, and INKT

How does Passage Bio compare to eXoZymes?

Do analysts prefer EXOZ or PASG?

Which has higher earnings and valuation, EXOZ or PASG?

Does the media prefer EXOZ or PASG?

Which has more volatility & risk, EXOZ or PASG?

Do institutionals and insiders believe in EXOZ or PASG?

Is EXOZ or PASG more profitable?

Summary

How does Passage Bio compare to INmune Bio?

Does the media favor PASG or INMB?

Is PASG or INMB more profitable?

Which has better earnings and valuation, PASG or INMB?

Do institutionals and insiders believe in PASG or INMB?

Do analysts rate PASG or INMB?

Which has more volatility & risk, PASG or INMB?

Summary

How does Passage Bio compare to Prima BioMed?

Which has better valuation & earnings, IMMP or PASG?

Does the media prefer IMMP or PASG?

Do analysts recommend IMMP or PASG?

Is IMMP or PASG more profitable?

Do institutionals & insiders hold more shares of IMMP or PASG?

Which has more volatility & risk, IMMP or PASG?

Summary

How does Passage Bio compare to Elicio Therapeutics?

Does the media prefer ELTX or PASG?

Do institutionals and insiders hold more shares of ELTX or PASG?

Do analysts rate ELTX or PASG?

Which has more risk & volatility, ELTX or PASG?

Is ELTX or PASG more profitable?

Which has better earnings & valuation, ELTX or PASG?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Does the media prefer INKT or PASG?

Which has more volatility & risk, INKT or PASG?

Do insiders & institutionals hold more shares of INKT or PASG?

Do analysts prefer INKT or PASG?

Is INKT or PASG more profitable?

Which has preferable valuation and earnings, INKT or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools